Evidence map›Paper›PMID 41656423›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Clinical research analysis of [

Zijuan Rao, Jiao Ma, Yangqing Jiangchu, Weiyu Yang, Fengyu Zhang, Meiling Hu, Chunyin Zhang, Yue Chen

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zijuan RaoDepartment of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China.
Jiao MaDepartment of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China.
Yangqing JiangchuDepartment of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China.
Weiyu YangDepartment of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China.
Fengyu ZhangDepartment of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China.
Meiling HuDepartment of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China.
Chunyin ZhangDepartment of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China.
Yue ChenDepartment of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China. chenyue5523@126.com.

Funding

Southwest Medical University 2024LCYXZX01
6 · The paper itself

Abstract

objectiveThe aim of this evaluation was to identify the safety and efficacy for [

methodsMetastatic castration-resistant prostate cancer patients after [

resultsEighteen patients were treated per protocol with a mean activity of 6.1 MBq in each cycle. 72.22% had a PSA decline at any degree, 55.56% had a PSA decline at more than 50%, and 38.89% had a PSA decline at more than 80%. According to PSMA PET progression criteria, disease control was achieved in 38.89% of the patients. The median progression-free survival under [

conclusionFor metastatic castration-resistant prostate cancer patients intolerant or unresponsive to [

Indexed as

ActiniumDipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overHumansMaleMiddle AgedNeoplasm MetastasisPositron Emission Tomography Computed TomographyProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsRetrospective Studies(225)Ac-PSMA-617ActiniumDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177lutetium (177Lu) vipivotide tetraxetanProstate-Specific AntigenRadioisotopesRadiopharmaceuticals[177Lu]Lu[225Ac]AcmCRPCPSA responsePSMA

Identifiers

PMID41656423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.